Docoh
Loading...

25 results

Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
Stock, or Common Stock issuable upon the exercise of options or other equity awards, in each case granted pursuant to any stock option, stock bonus
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
compensation, in exchange for cancellation of a compensation right, or as a bonus. Transferability. Awards are not transferable other than … of the following events, without the Participant’s advance written consent: a material reduction in the Participant’s base salary or cash bonus opportunity; (ii
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
of the capital stock of the Company or its subsidiary. The description of the Company’s stock option, stock bonus and other stock plans or arrangements … , medical, disability, fringe benefit, bonus, incentive, deferred compensation, employee loan and all other employee benefit plans, agreements, programs
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
, 2017 through bonus depreciation and an indefinite tax loss carryforward period for losses incurred after December 31, 2017. However, these tax-loss
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
capital expenditures made after September 27, 2017 through bonus depreciation and an indefinite tax loss carryforward period for losses incurred after
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
for accelerated deductions of certain capital expenditures made after September 27, 2017 through bonus depreciation and an indefinite tax loss carryforward
S-1/A
EX-1.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
subsidiary. The description of the Company’s stock option, stock bonus and other stock plans or arrangements (the “Company Stock Plans”), and the options … , bonus, incentive, deferred compensation, employee loan and all other employee benefit plans, agreements, programs, policies or other arrangements
S-1/A
EX-10.5
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
the Participant’s advance written consent: (i) a material reduction in the Participant’s base salary or cash bonus opportunity; (ii) a material adverse … compensation, in exchange for cancellation of a compensation right, or as a bonus. 13. Transferability. Awards are not transferable other than
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
expenditures made after September 27, 2017 through bonus depreciation and an indefinite tax loss carryforward period for losses incurred after December 31
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
deductions of certain capital expenditures made after September 27, 2017 through bonus depreciation and an indefinite tax loss carryforward period
S-1
PCSA Processa Pharmaceuticals Inc
13 Dec 19
IPO registration
5:32pm
deductions of certain capital expenditures made after September 27, 2017 through bonus depreciation and an indefinite tax loss carryforward period
DEF 14A
PCSA Processa Pharmaceuticals Inc
26 Apr 19
Definitive proxy
5:02pm
is entitled, such as in payment of director fees, in lieu of cash compensation, in exchange for cancellation of a compensation right, or as a bonus … ) a material reduction in the Participant’s base salary or cash bonus opportunity; (ii) a material adverse change in the Participant’s duties
10-K/A
2018 FY
PCSA Processa Pharmaceuticals Inc
5 Apr 19
Annual report (amended)
9:40pm
expenses. The TCJA also provides for accelerated deductions of certain capital expenditures made after September 27, 2017 through bonus depreciation
10-K
2018 FY
PCSA Processa Pharmaceuticals Inc
28 Mar 19
Annual report
5:25pm
interest expenses. The TCJA also provides for accelerated deductions of certain capital expenditures made after September 27, 2017 through bonus depreciation
424B3
PCSA Processa Pharmaceuticals Inc
9 Nov 18
Prospectus supplement
5:04pm
through bonus depreciation and an indefinite tax loss carryforward period for losses incurred after December 31, 2017. However, these tax loss carry
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Oct 18
IPO registration (amended)
4:19pm
of certain capital expenditures made after September 27, 2017 through bonus depreciation and an indefinite tax loss carryforward period for losses
S-1/A
PCSA Processa Pharmaceuticals Inc
9 Oct 18
IPO registration (amended)
5:32pm
after September 27, 2017 through bonus depreciation and an indefinite tax loss carryforward period for losses incurred after December 31, 2017. However
S-1/A
PCSA Processa Pharmaceuticals Inc
13 Sep 18
IPO registration (amended)
8:00pm
capital expenditures made after September 27, 2017 through bonus depreciation and an indefinite tax loss carryforward period for losses incurred after
S-1
PCSA Processa Pharmaceuticals Inc
29 Jul 18
IPO registration
8:00pm
capital expenditures made after September 27, 2017 through bonus depreciation and an indefinite tax loss carryforward period for losses incurred after
10-K/A
2017 FY
PCSA Processa Pharmaceuticals Inc
16 Apr 18
Annual report (amended)
8:00pm
also provides for accelerated deductions of certain capital expenditures made after September 27, 2017 through bonus depreciation and an indefinite tax